Skip to content
10-Q

Quarterly Report

EPIRUS Biopharmaceuticals, Inc.

0001558370-16-005832

← back to feed
Filed
May 10, 2016 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2016 · May 9, 2016 26.18M sh
Capex Q1 2016 · Mar 31, 2016 $70K
Short Term Debt Q1 2016 · Mar 31, 2016 $14.85M
Short Term Debt Q1 2016 · Dec 31, 2015 $14.83M
Cash And Equivalents Q1 2016 · Mar 31, 2016 $20.87M
Cash And Equivalents Q1 2016 · Dec 31, 2015 $31.52M
Cash And Equivalents Q1 2016 · Mar 31, 2015 $61.55M
Cash And Equivalents Q1 2016 · Dec 31, 2014 $21.46M
Stockholders Equity Q1 2016 · Mar 31, 2016 $26.17M
Stockholders Equity Q1 2016 · Dec 31, 2015 $36.37M
Current Liabilities Q1 2016 · Mar 31, 2016 $32.63M
Current Liabilities Q1 2016 · Dec 31, 2015 $33.28M
Total Liabilities Q1 2016 · Mar 31, 2016 $35.18M
Total Liabilities Q1 2016 · Dec 31, 2015 $35.9M
Current Assets Q1 2016 · Mar 31, 2016 $25.69M
Current Assets Q1 2016 · Dec 31, 2015 $35.25M
Total Assets Q1 2016 · Mar 31, 2016 $61.34M
Total Assets Q1 2016 · Dec 31, 2015 $72.26M
Sga Expense Q1 2016 · Mar 31, 2016 $6.47M
Sga Expense Q1 2016 · Mar 31, 2015 $4.17M
Rd Expense Q1 2016 · Mar 31, 2016 $10.34M
Rd Expense Q1 2016 · Mar 31, 2015 $3.08M
Net Income Q1 2016 · Mar 31, 2016 −$16.27M
Net Income Q1 2016 · Mar 31, 2016 $155.03M
Net Income Q1 2016 · Mar 31, 2015 −$7.52M
Operating Income Q1 2016 · Mar 31, 2016 −$16.01M
Operating Income Q1 2016 · Mar 31, 2015 −$7.22M